We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-1.86%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$14.7B
AUM Growth
-$908M
Cap. Flow
-$379M
Cap. Flow %
-2.57%
Top 10 Hldgs %
84.38%
Holding
107
New
11
Increased
15
Reduced
16
Closed
4

Top Buys

Rank Stock Value
1
BCEL
Atreca, Inc. Class A Common Stock
BCEL
+$63.8M
2
ADPT icon
Adaptive Biotechnologies
ADPT
+$51.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$26M
4
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$22.4M
5
HRTX icon
Heron Therapeutics
HRTX
+$20M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$184M
2
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$97.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$69.5M
4
GHDX
Genomic Health, Inc.
GHDX
+$55.6M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$38.7M

Sector Composition

Rank Sector Weight
1 Healthcare 94.63%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BOLD
26
DELISTED
Audentes Therapeutics, Inc
BOLD
$57M 0.39%
1,506,438
-208,745
-12% -$8.02M
ADPT icon
27
Adaptive Biotechnologies
ADPT
$3.64B
$56.3M 0.38%
+1,165,411
New +$51.6M
BCRX icon
28
BioCryst Pharmaceuticals
BCRX
$2.47B
$54.5M 0.37%
14,382,673
-735,408
-5% -$4.43M
RARX
29
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$54.2M 0.37%
1,801,695
+978,582
+119% +$22.4M
MYOK
30
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$51M 0.35%
1,016,306
– –
DBVT
31
DBV Technologies
DBVT
$806M
$45.3M 0.31%
550,956
– –
KRYS icon
32
Krystal Biotech
KRYS
$10.8B
$41.7M 0.28%
1,034,674
+250,000
+32% +$8.17M
CBAY
33
DELISTED
Cymabay Therapeutics
CBAY
$40.9M 0.28%
5,707,411
– –
QURE icon
34
uniQure
QURE
$2.79B
$40.5M 0.28%
517,700
-87,300
-14% -$5.56M
KNSA icon
35
Kiniksa Pharmaceuticals
KNSA
$6.24B
$37.9M 0.26%
2,799,577
-200,423
-7% -$3.11M
ZYME icon
36
Zymeworks
ZYME
$1.64B
$37.6M 0.26%
1,708,472
– –
NGNE icon
37
Neurogene
NGNE
$675M
$25.8M 0.18%
546,708
– –
AXSM icon
38
Axsome Therapeutics
AXSM
$11.9B
$19.9M 0.14%
772,286
-427,714
-36% -$8.57M
XNCR icon
39
Xencor
XNCR
$1.47B
$17.5M 0.12%
428,120
– –
MRUS
40
DELISTED
Merus
MRUS
$17M 0.12%
1,160,014
– –
ACOR
41
DELISTED
Acorda Therapeutics
ACOR
$15.4M 0.1%
16,760
+14,326
+589% +$17.6M
LJPC
42
DELISTED
La Jolla Pharmaceutical Company
LJPC
$14.4M 0.1%
1,559,231
+1,053,991
+209% +$7.94M
AIMT
43
DELISTED
Aimmune Therapeutics
AIMT
$14M 0.1%
673,908
– –
ACGN
44
DELISTED
Aceragen Inc
ACGN
$12.3M 0.08%
271,202
-13,782
-5% -$652K
PTGX icon
45
Protagonist Therapeutics
PTGX
$8.74B
$12.1M 0.08%
995,082
+591,189
+146% +$6.54M
MRKR icon
46
Marker Therapeutics
MRKR
$19.3M
$11.9M 0.08%
150,000
– –
SYRE icon
47
Spyre Therapeutics
SYRE
$8.75B
$11.7M 0.08%
68,544
– –
ASMB icon
48
Assembly Biosciences
ASMB
$507M
$10.8M 0.07%
66,937
+54,555
+441% +$10.4M
SGMO
49
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$10.8M 0.07%
999,823
– –
CPRX
50
DELISTED
Catalyst Pharmaceutical
CPRX
$9.83M 0.07%
2,559,461
-340,539
-12% -$1.47M
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2019 Portfolio in Review

As of Q2 2019, Baker Bros. Advisors held 107 positions worth $14.7B, down 5.8% from $15.6B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Baker Bros. Advisors's Q2 2019 filing shows 11 new, 15 increased, 16 reduced and 4 closed positions. Its largest new stake was Atreca, Inc. Class A Common Stock: 3,532,760 shares worth $66.6M. The largest sale was Incyte, an estimated $184M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q2 2019 buy was Atreca, Inc. Class A Common Stock: 3,532,760 shares worth $66.6M.
  • Baker Bros. Advisors added most to Neurocrine Biosciences in Q2 2019, an estimated $26M increase.
  • Baker Bros. Advisors's biggest Q2 2019 reduction was Incyte, cutting an estimated $184M.
  • Baker Bros. Advisors fully exited Clementia Pharmaceuticals Inc. in Q2 2019, selling an estimated $97.2M.
  • Baker Bros. Advisors's ten largest holdings make up 84% of its $14.7B portfolio in Q2 2019.
  • Baker Bros. Advisors opened 11 new positions and closed 4 in Q2 2019.
  • Baker Bros. Advisors's portfolio value fell 5.8% quarter-over-quarter to $14.7B.

Based on Baker Bros. Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.